Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.73 +7.5%	$2.45	$1.78 ▼ $10.14	$57.03M	0.7	262,237 shs	107,528 shs
ATRA Atara Biotherapeutics	$9.30 +0.8%	$7.94	$5.01 ▼ $18.71	$55.44M	0.18	116,524 shs	30,021 shs
CLLS Cellectis	$2.15 +35.2%	$1.49	$1.10 ▼ $2.43	$119.50M	2.91	147,838 shs	1.27 million shs
INBX Inhibrx Biosciences	$22.96 +5.5%	$14.49	$10.80 ▼ $23.46	$332.46M	-0.04	97,712 shs	162,890 shs
KRYS Krystal Biotech	$150.41 +1.5%	$135.59	$122.80 ▼ $219.34	$4.35B	0.67	286,150 shs	265,292 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+7.48%	+22.42%	+10.98%	-15.48%	-65.49%
ATRA Atara Biotherapeutics	+0.76%	+8.39%	+5.44%	+55.52%	-11.17%
CLLS Cellectis	+35.22%	+34.38%	+61.65%	+47.26%	+2.87%
INBX Inhibrx Biosciences	+5.47%	+25.12%	+57.58%	+94.74%	+72.76%
KRYS Krystal Biotech	+1.51%	+7.64%	+9.73%	-11.07%	-25.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.5706 of 5 stars	3.4	4.0	4.8	2.7	2.5	0.6
ATRA Atara Biotherapeutics	4.5971 of 5 stars	3.3	3.0	4.7	4.4	2.5	0.6
CLLS Cellectis	3.4421 of 5 stars	3.5	4.0	0.0	3.3	2.5	0.6
INBX Inhibrx Biosciences	2.2504 of 5 stars	0.0	3.0	4.6	2.2	1.7	1.3
KRYS Krystal Biotech	4.6549 of 5 stars	3.5	1.0	4.7	2.9	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	771.79% Upside
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	90.86% Upside
CLLS Cellectis	3.00	Buy	$4.00	86.05% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
KRYS Krystal Biotech	3.00	Buy	$213.75	42.11% Upside

Current Analyst Ratings Breakdown

Latest KRYS, CLLS, INBX, ATRA, and ADVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	57.03	N/A	N/A	$3.40 per share	0.80
ATRA Atara Biotherapeutics	$199.73M	0.28	N/A	N/A	($16.89) per share	-0.55
CLLS Cellectis	$49.22M	2.43	N/A	N/A	$2.36 per share	0.91
INBX Inhibrx Biosciences	$200K	1,662.30	$120.84 per share	0.19	$9.23 per share	2.49
KRYS Krystal Biotech	$290.52M	14.96	$4.71 per share	31.95	$32.90 per share	4.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.20	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	36.16	14.92	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)

Latest KRYS, CLLS, INBX, ATRA, and ADVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	INBX Inhibrx Biosciences	-$2.92	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	N/A	N/A	N/A	$4.23 million	N/A
8/5/2025	N/A	CLLS Cellectis	-$0.15	N/A	N/A	N/A	$10.07 million	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
ATRA Atara Biotherapeutics	N/A	0.57	0.57
CLLS Cellectis	0.44	1.67	1.67
INBX Inhibrx Biosciences	1.04	5.12	5.12
KRYS Krystal Biotech	N/A	9.65	9.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
ATRA Atara Biotherapeutics	70.90%
CLLS Cellectis	63.90%
INBX Inhibrx Biosciences	82.46%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
ATRA Atara Biotherapeutics	4.00%
CLLS Cellectis	16.41%
INBX Inhibrx Biosciences	N/A
KRYS Krystal Biotech	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	N/A	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable

KRYS, CLLS, INBX, ATRA, and ADVM Headlines

Recent News About These Companies

William Blair Lowers Earnings Estimates for Krystal Biotech

1 hour ago | marketbeat.com

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis

July 14 at 11:49 AM | ophthalmologytimes.comO

Krystal Biotech, Inc. (NASDAQ:KRYS) Holdings Cut by TimesSquare Capital Management LLC

July 14 at 8:54 AM | marketbeat.com

William Blair Forecasts Lower Earnings for Krystal Biotech

July 14 at 2:39 AM | marketbeat.com

William Blair Reduces Earnings Estimates for Krystal Biotech

July 13 at 2:17 AM | americanbankingnews.com

Suma Krishnan Sells 200 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

July 12 at 6:25 AM | insidertrades.com

Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 200 Shares of Stock

July 11, 2025 | marketbeat.com

Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 6,927 Shares of Stock

July 11, 2025 | marketbeat.com

Citi raises Krystal Biotech stock price target to $176 on KB801 trial ...

July 11, 2025 | investing.com

Q2 EPS Estimates for Krystal Biotech Decreased by Analyst

July 11, 2025 | marketbeat.com

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

July 10, 2025 | zacks.com

Principal Financial Group Inc. Has $22.78 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

July 10, 2025 | marketbeat.com

Pittsburgh tech's future isn't guaranteed, CEO warns

July 9, 2025 | msn.com

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

July 9, 2025 | globenewswire.com

Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

July 9, 2025 | marketbeat.com

High Insider Ownership In 3 Promising Growth Companies

July 8, 2025 | finance.yahoo.com

Krystal Biotech Inc. Research & Ratings | KRYS - Barron's

July 3, 2025 | barrons.com

Krystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

July 3, 2025 | finance.yahoo.com

Clear Street Initiates Coverage of Krystal Biotech (KRYS) with Buy Recommendation

July 3, 2025 | msn.com

Peering Into Krystal Biotech's Recent Short Interest

July 3, 2025 | benzinga.com

Krystal Biotech Q2 EPS Estimate Lowered by HC Wainwright

July 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS, CLLS, INBX, ATRA, and ADVM Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.73 +0.19 (+7.48%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.72 -0.01 (-0.40%)

As of 07:00 AM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Atara Biotherapeutics NASDAQ:ATRA

$9.30 +0.07 (+0.76%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$9.42 +0.12 (+1.29%)

As of 08:29 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Cellectis NASDAQ:CLLS

$2.15 +0.56 (+35.22%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.28 +0.13 (+5.81%)

As of 08:44 AM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Inhibrx Biosciences NASDAQ:INBX

$22.96 +1.19 (+5.47%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$23.46 +0.50 (+2.18%)

As of 08:42 AM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Krystal Biotech NASDAQ:KRYS

$150.41 +2.24 (+1.51%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$149.58 -0.82 (-0.55%)

As of 08:36 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time